for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

ABIOMED, Inc.

ABMD.O

Latest Trade

284.83USD

Change

3.41(+1.21%)

Volume

91,897

Today's Range

277.94

 - 

287.28

52 Week Range

119.01

 - 

319.19

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
281.42
Open
279.22
Volume
91,897
3M AVG Volume
6.51
Today's High
287.28
Today's Low
277.94
52 Week High
319.19
52 Week Low
119.01
Shares Out (MIL)
45.05
Market Cap (MIL)
12,677.20
Forward P/E
--
Dividend (Yield %)
--

Next Event

Q2 2021 ABIOMED Inc Earnings Call

Latest Developments

More

Abiomed Q1 GAAP Earnings Per Share $0.98

FDA Approves Data Streaming From The Impella Console

FDA Approves Abiomed’s First-In-Human Trial Of Impella ECP

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About ABIOMED, Inc.

ABIOMED, Inc. is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart. The Company's product portfolio includes the Impella 2.5, Impella CP, Impella RP, Impella LD, Impella 5.0 and AB5000. The Company's products are used in the cardiac catheterization lab (cath lab), by interventional cardiologists, the electrophysiology lab, the hybrid lab and in the heart surgery suite by heart surgeons.

Industry

Medical Equipment & Supplies

Contact Info

22 CHERRY HILL DR

DANVERS, MA

01923-2575

United States

+1.978.7775410

http://www.abiomed.com/

Executive Leadership

Michael R. Minogue

Chairman of the Board, President, Chief Executive Officer

Todd A. Trapp

Chief Financial Officer, Vice President

David M. Weber

Chief Operating Officer, Senior Vice President

Marc A. Began

Vice President, General Counsel, Secretary

Michael G. Howley

Vice President and General Manager, Global Sales

Key Stats

2.33 mean rating - 9 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.6K

2019

0.8K

2020

0.8K

2021(E)

0.8K
EPS (USD)

2018

2.450

2019

5.100

2020

4.430

2021(E)

4.417
Price To Earnings (TTM)
80.89
Price To Sales (TTM)
15.88
Price To Book (MRQ)
11.50
Price To Cash Flow (TTM)
70.34
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
14.66
Return on Equity (TTM)
13.36

Latest News

Latest News

Abiomed heart pump gets second FDA emergency use nod for COVID-19 patients

Medical device maker Abiomed Inc <ABMD.O> said on Tuesday the U.S. Food and Drug Administration granted its left-sided heart pumps emergency use authorization to help patients suffering from COVID-19-related heart and lung failures.

BRIEF-ABIOMED Says 2020 Total Compensation For CEO Michael Minogue $16.6 Mln Versus $19.2 Mln In 2019

* ABIOMED INC - 2020 TOTAL COMPENSATION FOR CEO MICHAEL MINOGUE $16.6 MILLION VERSUS $19.2 MILLION IN 2019

BRIEF-Abiomed Appoints Charles Simonton As New Chief Medical Officer

* ABIOMED APPOINTS NEW CHIEF MEDICAL OFFICER CHARLES SIMONTON, M.D. Source text for Eikon: Further company coverage:

BRIEF-FDA Approves Abiomed’s First-In-Human Trial Of Impella ECP

* FDA APPROVES ABIOMED’S FIRST-IN-HUMAN TRIAL OF IMPELLA ECP, WORLD’S SMALLEST HEART PUMP Source text for Eikon: Further company coverage:

FDA approves emergency use of Abiomed heart pump for COVID-19 patients

Abiomed Inc said on Monday the U.S. Food and Drug Administration has granted emergency use authorization for its temporary invasive heart pump to help patients suffering from COVID-19 related right heart failure.

BRIEF-Abiomed Announces Q4 FY 2020 Revenue Of $207 Million And 28.1% Operating Margin

* ABIOMED ANNOUNCES Q4 FY 2020 REVENUE OF $207 MILLION AND 28.1% OPERATING MARGIN

BRIEF-Abiomed’S Response To The Covid-19 Pandemic

* ABIOMED INC - IN FY21, ABIOMED WILL TRANSITION MAJORITY OF CO'S PATIENTS AND HOSPITALS TO IMPELLA CONNECT PLATFORM

Abiomed seeks records to fight whistleblower's retaliation claims

Heart pump maker Abiomed Inc on Wednesday sought to force an ex-employee to turn over records so that it could defend itself against claims that it fired him in retaliation for complaining about lavish meals the company bought doctors as kickbacks.

BRIEF-Abiomed Q4 GAAP EPS $0.80

* ABIOMED ANNOUNCES Q4 FY 2018 REVENUE OF $174 MILLION, UP 40%, AND TOTAL YEAR REVENUE OF $594 MILLION, UP 33%, OVER PRIOR YEAR

BRIEF-Abiomed Reports Q4 GAAP Earnings Per Share $0.80

* ABIOMED ANNOUNCES Q4 FY 2018 REVENUE OF $174 MILLION, UP 40%, AND TOTAL YEAR REVENUE OF $594 MILLION, UP 33%, OVER PRIOR YEAR

BRIEF-Abiomed Announces European Approval For Impella 5.5(Tm)

* ABIOMED ANNOUNCES EUROPEAN APPROVAL (CE MARKING) FOR IMPELLA 5.5(TM) AND FIRST PATIENT TREATED AT UNIVERSITY HEART CENTER HAMBURG Source text for Eikon: Further company coverage:

BRIEF-Abiomed Announces European Approval (CE Marking) For Impella 5.5™

* ABIOMED ANNOUNCES EUROPEAN APPROVAL (CE MARKING) FOR IMPELLA 5.5™ AND FIRST PATIENT TREATED AT UNIVERSITY HEART CENTER HAMBURG Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

BRIEF-Abiomed Receives FDA Approval For Impella Cp® With Smartassist™ And Optical Sensor

* ABIOMED RECEIVES FDA APPROVAL FOR IMPELLA CP® WITH SMARTASSIST™ AND OPTICAL SENSOR

BRIEF-Abiomed To Appoint Todd Trapp Chief Financial Officer

* ABIOMED TO APPOINT NEW CHIEF FINANCIAL OFFICER TODD A. TRAPP

Abiomed to pay $3.1 million to settle case over lavish doctor meals

Abiomed Inc has agreed to pay $3.1 million to resolve a U.S. probe into allegations that it sought to get doctors to use a line of heart pumps it produced by buying them lavish meals at some of the most expensive restaurants in the United States.

BRIEF-Abiomed Says Entered Settlement With U.S. DoJ Resolving Claims Related To Employee Meals

* ABIOMED - ON MARCH 6, ENTERED SETTLEMENT WITH U.S. DOJ RESOLVING CLAIMS ON CO'S REIMBURSEMENT OF EMPLOYEE EXPENSES FOR MEALS WITH HEALTHCARE PROVIDERS Source text: (http://bit.ly/2G9t6b6) Further company coverage:

Heart pump maker Abiomed settles U.S. kickback probe for $3.1 mln

Abiomed Inc has agreed to pay $3.1 million to resolve a U.S. investigation into allegations that it sought to induce doctors into using a line of heart pumps it produced by buying them lavish meals.

BRIEF-Abiomed Receives Approval For Expanded FDA Indication For High Risk PCI Procedures

* ABIOMED RECEIVES APPROVAL FOR EXPANDED FDA INDICATION FOR HIGH RISK PERCUTANEOUS CORONARY INTERVENTION (PCI) PROCEDURES Source text for Eikon: Further company coverage:

BRIEF-Abiomed Receives Approval For Expanded FDA Indication For Cardiomyopathy With Cardiogenic Shock

* ABIOMED RECEIVES APPROVAL FOR EXPANDED FDA INDICATION FOR CARDIOMYOPATHY WITH CARDIOGENIC SHOCK

BRIEF-Abiomed Q3 Gaap Earnings Per Share $0.29

* ABIOMED ANNOUNCES Q3 FY 2018 RECORD REVENUE OF $154 MILLION, UP 34% OVER PRIOR YEAR

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up